Progress in Neurology and Psychiatry is a pivotal journal published by John Wiley & Sons Ltd, dedicated to advancing the fields of neurology and psychiatry. With a robust history dating back to its establishment, this esteemed journal holds a consistent Q3 ranking in 2023 across several categories including Neurology, Clinical Neurology, Psychiatry, and Mental Health, signifying its significant contribution to the scientific community. This journal serves as a vital source of knowledge and insight, publishing original research, reviews, and case studies that explore the intricacies of neurological and psychiatric disorders. Although it does not offer open access, the journal remains accessible to a wide audience through institutional subscriptions. By fostering a platform for scholarly discourse, Progress in Neurology and Psychiatry aims to bridge the gap between research and practice, ultimately enhancing the quality of care for individuals with neurological and psychiatric conditions. Researchers, clinicians, and students are encouraged to engage with the journal's comprehensive content to stay informed of the latest developments and emerging trends in these critical fields of medicine.

Brain Communications is an esteemed, open-access academic journal published by Oxford University Press since 2019, focusing on the dynamic field of neuroscience. With a dedicated ISSN and an E-ISSN of 2632-1297, this journal aims to address the intricate relationships between brain functions, psychiatric disorders, and neurobiological mechanisms. The journal stands out in the academic realm, holding a prestigious Q1 ranking across several categories, including Biological Psychiatry, Cellular and Molecular Neuroscience, Neurology, and Psychiatry and Mental Health for 2023. Notably, it has also secured impressive Scopus ranks in various neuroscience and psychiatry fields, evidencing its commitment to high-quality research. With an impact factor reflective of its growing influence, Brain Communications provides accessible research findings to professionals, researchers, and students alike, fostering a deeper understanding of complex neurological phenomena. This innovative journal is pivotal for anyone involved in advancing knowledge in neuroscience and mental health.

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, a premier academic journal published by TAYLOR & FRANCIS LTD, stands at the forefront of interdisciplinary research in the fields of Biological Psychiatry, Psychiatry, and Mental Health. Based in the United Kingdom, this esteemed journal (ISSN: 1562-2975; E-ISSN: 1814-1412) has become increasingly influential since its inception in 2000, with a remarkable impact factor that reflects its high-quality research contributions. The journal is consistently ranked in the Q1 and Q2 categories across various relevant indices, demonstrating its reputation for excellence within the academic community. With Scopus rankings placing it in the top 20th percentile for Psychiatry and Mental Health, the WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY serves as a vital resource for researchers, professionals, and students seeking to further their understanding of the intricate relationship between biological processes and psychiatric phenomena. Despite being a traditional access journal, it possesses a robust scope that encompasses groundbreaking studies, reviews, and advancements in the understanding of mental health disorders, underlining its importance as a key reference in the advancement of psychiatric science and therapeutic practices.

Current Neuropharmacology is a premier journal dedicated to advancing the field of neuropharmacology, published by Bentham Science Publishers Ltd in the United Arab Emirates. As a leader in its domain, this journal has achieved a remarkable position in 2023, with Q1 rankings across several categories including Medicine (miscellaneous), Neurology, and Pharmacology. With a robust focus on the latest research related to pharmacological treatments and their neurological implications, Current Neuropharmacology features cutting-edge studies that inform clinical practices and psychiatric care. Although not open access, the journal offers both print and electronic formats to cater to a diverse audience of researchers, healthcare professionals, and students keen on accessing vital information in neuropharmacology. Its high impact within the academia is underscored by impressive Scopus rankings, confirming its importance as a vital resource for the ongoing exploration of mental health and neurotherapeutic innovations. With an engaging scope that encompasses emerging discoveries and clinical advancements, Current Neuropharmacology continues to be an essential platform for scholarly communication in the evolving landscape of neuroscience and pharmacology.

Neuropsychopharmacology Reports is a leading open-access journal published by WILEY, dedicated to advancing the fields of clinical psychology, pharmacology, psychiatry, and mental health. Established in 2018, the journal aims to disseminate high-quality research findings, critical reviews, and innovative methodologies that elucidate the complexities of neuropsychopharmacology in enhancing mental health outcomes. With an impressive impact indicated by its Q2 rankings in several categories including Clinical Psychology and Pharmacology (medical) as of 2023, Neuropsychopharmacology Reports stands out as a vital resource for researchers, professionals, and students keen on exploring the interplay between pharmacological interventions and psychological well-being. The journal’s open-access nature ensures that critical advancements in this rapidly evolving field are readily available to a global audience, fostering collaboration and discourse among scholars and practitioners alike. Building on its indexed status with Scopus, the journal is positioned as a noteworthy contributor to ongoing discussions and developments in psychiatry and medical pharmacology.

The INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, published by OXFORD UNIV PRESS, is a leading open-access journal in the fields of pharmacology and psychiatry, with an impressive impact factor reflecting its prominence in academic research. Since its inception in 1998, the journal has provided a crucial platform for the publication of high-quality research, offering insights into the effects of neuropharmacological agents on mental health. As of 2023, it ranks in the Q1 category for both Pharmacology and Psychiatry & Mental Health, underscoring its relevance and authority within the scientific community. With notable rankings in various medical subspecialties, it attracts contributions that advance our understanding of psychiatric disorders and therapeutic strategies. The accessible nature of the journal, following its transition to open access in 2015, has expanded its reach, making knowledge and findings readily available to researchers, professionals, and students globally. This commitment to disseminating impactful research ensures the journal remains at the forefront of neuropsychopharmacological advancements.

Asia-Pacific Psychiatry is a leading academic journal published by WILEY, focused on the diverse and rapidly evolving fields of psychiatry and mental health within the Asia-Pacific region. With an ISSN of 1758-5864 and an E-ISSN of 1758-5872, this journal has been recognized for its significant impact, holding a Q1 ranking in Medicine (miscellaneous) and a Q2 ranking in Psychiatry and Mental Health as of 2023. Its commendable Scopus ranking places it at Rank #83 out of 567 in its category, highlighting its influence and relevance in contemporary research. The journal aims to facilitate the dissemination of high-quality research, reviews, and clinical insights that address mental health challenges, promote global understanding, and encourage collaboration among professionals and academics. Although it is not an open-access journal, the high impact factor underscores its value in the scholarly community, making it an essential resource for researchers, clinicians, and students dedicated to enhancing mental health practices and policies in the region and beyond.

Basic and Clinical Neuroscience, published by Iran University of Medical Sciences, is a distinguished open-access journal that has been operational since 2009, providing a platform for the dissemination of significant research in the fields of neuroscience and neurology. With the ISSN 2008-126X and E-ISSN 2228-7442, this journal serves as a vital resource for researchers, clinicians, and students by facilitating access to the latest findings and advancements in cellular and molecular neuroscience as well as clinical neurology. Although currently rated in Q4 for Cellular and Molecular Neuroscience and Q3 for Clinical Neurology as of 2023, it aims to enhance its standing through the publication of high-quality, peer-reviewed research. The journal has achieved a Scopus rank placing it in the 38th percentile for Neurology and the 13th percentile for Neuroscience, indicating a growing recognition of its contributions. With its commitment to open access, Basic and Clinical Neuroscience not only contributes to the scientific community in Iran but also strives to connect researchers worldwide, fostering collaborative efforts in tackling complex neurological challenges.

Behavioural Pharmacology is a distinguished academic journal published by Lippincott Williams & Wilkins, focusing on the intricate relationship between pharmacology, psychiatry, and behavioral science. With an ISSN of 0955-8810 and an E-ISSN of 1473-5849, this journal serves as a vital platform for researchers and professionals dedicated to exploring the pharmacological mechanisms underlying behavior and mental health. Operating with a robust track record since its inception in 1992, it has established itself in the academic community, as reflected by its Q3 rankings in both the pharmacology and psychiatry categories for 2023. Additionally, the journal holds a credible position in Scopus rankings, with a percentile ranking indicative of significant contributions to the fields of pharmacology and psychiatry. Aimed at advancing knowledge and disseminating research in the behavioral pharmacology domain, this journal is an essential resource for students, researchers, and clinical professionals seeking to stay at the forefront of this rapidly evolving field. While it is not an open access journal, the rich content and research findings published here continue to foster collaboration and innovation within the community, making it a crucial reference point for current and future studies.

NEUROSCIENCE LETTERS is a distinguished journal published by ELSEVIER IRELAND LTD, focusing on disseminating impactful research across the field of neuroscience. With its ISSN 0304-3940 and E-ISSN 1872-7972, the journal serves as a vital platform for researchers, professionals, and students aiming to explore the complexities of nervous system function and related disorders. Since its inception in 1975, NEUROSCIENCE LETTERS has contributed significantly to the field, currently positioned in the Q3 category for Miscellaneous Neuroscience, with a respectable Scopus rank of 52/113, placing it in the 54th percentile among its peers. The journal is published in Ireland and offers a comprehensive repository of scientific insights, methodologies, and innovative findings that advance our understanding of neurological phenomena. While not an open-access journal, it remains an essential resource for the latest advances in neuroscience research and the academic community’s collective knowledge.